- Q3 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 14, 2024$1.59 (-2.45%)Earnings
- Q2 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 14, 2023$1.45 (+20.83%)Earnings
- Q1 2024 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2023$2 (-0.99%)Earnings
- Immunoprecise Antibodies Ltd To Participate in an Interview Hosted by Market Radius Research TranscriptJul 19, 2023
- Q4 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 07, 2023$2.99 (-1.32%)Earnings
- Immunoprecise Antibodies Ltd at Smallcap Discoveries TranscriptJun 28, 2023
- Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q3 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptMar 16, 2023$3.37 (-10.13%)Earnings
- Q2 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 15, 2022$4.9 (-8.58%)Earnings
- Q1 2023 Immunoprecise Antibodies Ltd Earnings Call TranscriptSep 14, 2022$4.85 (-9.85%)Earnings
- Q4 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptJul 29, 2022$4.23 (-7.03%)Earnings
- Q2 2022 Immunoprecise Antibodies Ltd Earnings Call TranscriptDec 13, 2021$5.06 (-9.96%)Earnings
- Immunoprecise Antibodies Ltd LifeScience Webinar TranscriptApr 28, 2021
Q4 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Good morning, ladies and gentlemen. Thank you for joining us today for IPA's earnings call covering the fourth quarter and full fiscal year of 2023. I am Regina and I have the privilege of hosting this call.
Before we commence, I would like to draw your attention to the fact that our discussion today may include forward-looking statements. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from what we expressed or implied. We strongly encourage you to review our filings with the Securities and Exchange Commission for a comprehensive discussion of these risks and uncertainties. IPA remains committed to complying with legal requirements and will update forward-looking statements only as mandated by law.
During today's conference call as well as in the accompanying presentation slides, we will be employing non-GAAP financial measures to assist investors and analysts and comprehending APA's business performance. Adjusted EBITDA, in particular, allows for meaningful comparisons and analysis of trends in our business over
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)